key: cord-1044029-4urs9vr1 authors: Abrams, Elissa M.; Primeau, Marie-Noel; Kim, Harold; Gerdts, Jennifer; Chan, Edmond S. title: Increasing awareness of the low risk of severe reaction at infant peanut introduction: Implications during COVID-19 and beyond date: 2020-09-04 journal: J Allergy Clin Immunol Pract DOI: 10.1016/j.jaip.2020.08.044 sha: 8615b259c9c69dd9607ace27738a6f12386c5010 doc_id: 1044029 cord_uid: 4urs9vr1 nan provide reassurance about the safety of early peanut food introduction, even during the 51 current COVID-19 pandemic. 52 53 The risk of a severe reaction on first ingestion of peanut in infancy is extremely low 54 Infant anaphylaxis tends to be mild, and mortality upon first ingestion during infant food 55 introduction has not been described. 4 Firstly, even if anaphylaxis were to occur, evidence from 56 the ED shows that infant anaphylaxis is milder than in older children. In a recent large 57 retrospective cohort study of 1518 infants and children presenting with food allergy reactions 58 to the ED in California, infants presented with respiratory symptoms less often than children 59 age 1 and ages 2 to 4 years (6.8%, 16.1%, and 23.9% respectively, P<.001). 5 Another 60 retrospective review of 357 children with food-induced anaphylaxis seen in the ED in Chicago 61 similarly noted lower frequency of respiratory symptoms in infants with wheezing in only 2% of 62 infants <12 months compared to 19% for 12-23 months (P=.008), 31% for 2-6 years (P<.001), 63 and 22% for >6 years (P=.001), and more frequent skin involvement (P<.001). 6 Also, egg 5,6 or 64 cows milk 6 were more common causes of food-induced reactions presenting to the ED in 65 infancy, instead of peanut. 66 Besides the relative mildness of infant anaphylaxis when it occurs, large observational 67 studies and randomized controlled trials (RCTs) have found early introduction of peanut in 68 infancy to be safe, with anaphylaxis being extremely low. In the Learning Early About Peanut 69 (LEAP) study, only 7/319 (2.2%) of the high-risk infants randomly assigned to the peanut 70 consumption group had a positive oral food challenge (OFC) at baseline. 7 Symptoms were 71 predominantly cutaneous and were treated with oral antihistamines (6/7) and oral steroids 72 (1/6); none of the reactions required epinephrine. In the population-based HealthNuts cohort, 73 of those infants who introduced peanut at home by 12 months of age, reactions of any severity 74 were rare 32/1320 (2.4%) and only 1/1320 (0.08%) had possible anaphylaxis due to wheeze 75 (although later tolerated peanut on OFC at 14 months of age). 8,9 Using higher risk infants as the 76 denominator, 1/185 (0.54%) had possible anaphylaxis due to wheeze. Using lower risk infants 77 as the denominator, 0/1135 (0%) had possible anaphylaxis. 78 A longstanding major concern of some allergists has been the fear of presumed severe 79 reaction in infants with large positive screening SPTs prior to first ingestion (especially infants 80 with a history of eczema), because the LEAP study did not do baseline OFCs in infants with 81 SPT>4mm. To address this, a recent retrospective chart review of 84 infants that screened for 82 peanut sensitization using the NIAID guideline approach noted that of the 7 infants with 83 positive SPT of 3-7 mm who received an OFC, 3/7 (43%) reacted but all reactions were mild 84 (cutaneous and/or upper respiratory) and responded to antihistamines. 10 No anaphylaxis was 85 noted and epinephrine was not required, and of those with negative SPT, all infants introduced 86 peanut at home with no reaction. Another retrospective chart review included a larger number 87 of infants (70) who received OFCs after NIAID-based screening SPTs, that were even higher risk 88 (>75% had eczema and ~50% had egg sensitization). 11 The study noted overall high tolerance to 89 peanut on OFC (77%), and among infants with SPT>4mm, outcomes were very reassuring: 90 25/40 (63%) with SPT>4mm tolerated peanut, which included 13/18 (72%) with SPT 5-7 mm 91 and 12/22 (55%) with SPT>7 mm. For the 16/70 (23%) who reacted at OFC, nine infants were 92 given epinephrine as a precaution for mild to moderate symptoms, with none having any 93 significant respiratory, cardiovascular, or neurologic symptoms. 94 Based on the above evidence, the key takeaways are that the risk of severe reaction to 95 peanut in infancy is extremely small, even among infants who experience anaphylaxis and even 96 among infants at very high-risk of developing peanut allergy. Therefore, peanut can be safely 97 introduced at home for all infants (including higher-risk infants), during COVID-19 and once the 98 pandemic has been controlled. 99 100 Moving beyond screening to address hesitancy among families 101 Some families may not be comfortable introducing peanut in infancy without some form 102 of pre-emptive evaluation, despite education of the above. However, pre-emptive screening 103 would be considered very low priority when resuming in-person clinical visits. 3 During COVID-104 19, some laboratories are closed and some allergy offices are exclusively virtual. Waiting for 105 screening with SPT and/or sIgE testing could result in delayed introduction and inadvertently 106 increase the risk of peanut allergy. In addition, some of the barriers to pre-emptive screening 107 including resource limitations, high rates of clinically irrelevant false positive tests, lack of 108 availability of infant OFCs and poor cost effectiveness are amplified during this time. 12 109 For families with hesitancy, a shared decision-making approach that reviews benefits 110 and risks is required, as is clear risk communication, including in the recognition and 111 management of anaphylaxis. 13 One novel approach for hesitancy that completely circumvents 112 screening and has recently been shown during COVID-19 to be feasible is virtual physician 113 supervised home peanut introduction, especially among higher risk infants. 14 114 This approach could be continued post COVID-19, especially for families living in remote areas, 115 settings where infant OFCs are unavailable, or settings where there are no local allergists. 116 117 Increasing awareness of the low risk of severe reaction at infant peanut introduction is needed 118 While food introduction during COVID-19 may be a significant concern for families, little 119 international guidance exists on the safety of early introduction during the pandemic. The 120 Canadian Pediatric Society has released a communication supporting early food introduction at 121 home among infants at risk despite COVID-19. 15 We now have a variety of newer data which 122 supports the extremely low risk of severe reaction upon infant first ingestion (even among 123 higher risk infants), that should be used to educate parents and inform statements from allergy 124 organizations. 125 J o u r n a l P r e -p r o o f COVID-19 gives us an opportunity to re-frame how we reassure families about the 126 extremely low risk of severe reaction upon infant food introduction. Even among infants at 127 high-risk of developing peanut allergy, there is evidence that early peanut ingestion at home is 128 very safe and now is the time to start de-medicalizing it. 129 COVID-19: 134 Pandemic Contingency Planning for the Allergy and Immunology Clinic A 137 Phased Approach to Resuming Suspended Allergy/Immunology Clinical Services Further fatal allergic reactions to food in the United 140 Department Outcomes in Young Children with Food Allergy Food-induced anaphylaxis in infants and children Randomized 147 trial of peanut consumption in infants at risk for peanut allergy Understanding the feasibility and implications of implementing early peanut introduction 151 for prevention of peanut allergy Earlier 153 ingestion of peanut after changes to infant feeding guidelines: The EarlyNuts study Real-life infant peanut allergy 156 testing in the post-NIAID peanut guideline world Low-dose peanut challenges can 159 facilitate infant peanut introduction regardless of skin prick test size Pros and cons of 162 pre-emptive screening programmes before peanut introduction in infancy Special Article: Risk Communication During COVID-19 Virtually supported 167 home peanut introduction during COVID-19 for at-risk infants Canadian Paediatric Society -Can we continue to recommend early 170 allergenic food introduction during a pandemic?